Member Info for Digger01

Surely that means cost will be down relative to selling in USD ? Except power ?

At least the product trial results are all positive to date, so we have something worth investing in. Patience required although disappointing, but that is common in biotech.

Steady increase in price of Gold, looking for good value Gold producing companies with production costs under control. That`s why I have joined the club here.

Volume is OK but this RNS does not give us any detail of the Cost of production which has been historically high. However, with the reduction in oil price, I would expect costs to have fallen or the certainly will do.

Does Scott not have enough on his plate already ? BOCA RATON, Fla., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Emergent Health Corp. (Pink Sheets:EMGE) announced today the appointment of three new members to its Board of Directors. Joining the Board of Directors are David P. Jones, Ph.D., M. Scott Maguire, MBA, and Robert S. McCoy, Jr. "We are delighted to announce the addition of our three newest Board members. All three embody the spirit of Emergent bringing talent, expertise and energy to the table. We are very fortunate to have them by our side," said Dr. John V. Cappello, Founder, and former President and Chief Executive Officer for Emergent.

All sounds simples ! Big companies and organisations have historically always backed this company presumably primarily based on the science. The science has not failed so I am personally confident that raising money should not be a problem. Here's to a good 2015 all ye faithful ones.

Anyone have any thoughts on today's' report ? No hint or mention of funding and SP continues to decline. All the product reports have been good and everything appears to be falling into place. But capital !! The buy price is very attractive at present, but at what risk ? I still have a good level of confidence but we are BIG cash burners without any sales.

Stated in the last quarterly filing SUBMITTED 14/11/2014. "The Company estimates that as of the date of the filing of this Form 10-Q, the Company has working capital available to fund its current business plan to the middle of the first quarter of 2015" "Based upon the progress of on-going discussions, the Company has a reasonable expectation that it will raise sufficient working capital to meet its obligations over the next twelve months" News must be fairly imminent but not necessarily this side of Xmas. However what will be any placing price ? Baxter will not be happy if its much under $1

I agree 100% and I am unfortunately in the same financial position. XEN, VRP,RRL,XEL,MXP - need I go on.? Forget the theory of a mixed sector portfolio - all round disaster. Guess what, to make things worse my Sipp provider Standard Life now offer 0% on cash bank balances so where do I "invest" ??? Also only covered by a single bank guarantee - Circa 80K where are we all heading ? Come on Xen, give us a nice Xmas surprise.

Stocktrade hold these for me in my SIPP (Standard life) - no problem at all.

I have bought recently through Stocktrade. No problem at all

Possibly correct, but remember that our Aim exit price converted to approx $0.4 but Baxter paid nearly $1 for 10.6 million shares, so Scott did a good selling job. Since then, we have got a lot closer to an EPO out licensing deal with continued good trial results. We also have excellent patent protection and of course other products under trial as well as the Dana Farber collaboration. So I have to be more optimistic favouring any placing at a likely higher premium to the bargain basement current SP level. We will soon see !

Good further results for Erepoxen and further referencing to out- licensing. Things are hotting up with good assets to encourage the short term investment.

Volume today, all signs of gathering momentum.

If you are happy to risk and wait - wait-wait - easy to buy through Stocktrade @ $0.25

Looks like we are focusing on the out licensing of Erepoxen as our first near revenue generating product. Any major development here will surely create the Nasdaq pathway.

I thought that we might have had some news on Oncohist by now ? I hope that Scott is still on the PR trail to gain support for investment ref Nasdaq - is this what they call Purgatory ?

Is this our new board ? They obviously couldn't cope with Leeson !

SP $0.40 = roughly 12.5p based on old Aim.

May 21 RNS Expected 2014 Milestones - NOT YET ADVISED TO THE MARKET. • Advance ongoing clinical development of OncoHist®, with planned U.S. IND filings for AML and an additional cancer indication • Secure U.S. Orphan Drug Designation for additional oncology indication for OncoHist® • Present interim data from Phase 2 Russia trial of OncoHist® in patients with refractory AML and Non Hodgkin's Lymphoma • Initiate Phase 2 trial of PulmoXen® for the treatment of cystic fibrosis, conducted by Russian partner, OJSC • In addition to these expected milestones, one of the primary goals of management and the Board is to seek a NASDAQ Capital Market uplist at the earliest practical date